Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Anticipation Builds for Blackbauds Quarterly Earnings Report

Elaine Mendonca by Elaine Mendonca
February 9, 2024
in Breaking News
0
Biotechnology Market Capitalization
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Blackbaud, a company listed on the NASDAQ as BLKB, is set to unveil its latest quarterly earnings report on February 12, 2024. Market analysts have projected an earnings per share (EPS) estimate of $1.05 for this period. Investors and enthusiasts of Blackbaud are eagerly anticipating the release, hoping that the company not only surpasses this estimate but also provides an optimistic outlook for future growth.

Over time, Blackbaud has consistently outperformed EPS estimates, which has often resulted in significant movements in its stock price. A prime example of this occurred in Q3 of 2023 when the company exceeded the EPS estimate by $0.15, leading to an 8.47% increase in its share price the following day. It’s worth noting, however, that stock price fluctuations can also be influenced by the company’s forward-looking statements and guidance, in addition to the earnings beat or miss.

Let’s take a closer look at Blackbaud’s recent earnings history:

– Q3 2023: The estimated EPS was $0.97, but the actual EPS came in at $1.12, resulting in an 8.47% price increase.
– Q2 2023: The estimated EPS was $0.93, but the actual EPS was $0.98, leading to a -1.05% price change.
– Q1 2023: The estimated EPS was $0.70, but the actual EPS turned out to be $0.72, resulting in a 4.11% price increase.
– Q4 2022: The estimated EPS was $0.60, but the actual EPS was $0.68, followed by a -5.36% price change.

Blackbaud’s stock performance has been positive over the past 52 weeks, with shares experiencing a 31.47% increase and currently trading at $80.67 as of February 7, 2024. This upward trend suggests that long-term shareholders may have a positive outlook leading up to the earnings release.

For those closely following Blackbaud’s financial journey and future earnings announcements, it is recommended to keep a close eye on their earnings calendar and other reliable financial resources.

BLKB Stock Shows Positive Performance on February 9, 2024: A Potential Growth Opportunity for Investors

On February 9, 2024, BLKB stock showed positive performance, trading near the top of its 52-week range and above its 200-day simple moving average. According to data from CNN Money, the price of BLKB shares increased by $0.31 since the market last closed, representing a rise of 0.38%. BLKB stock opened at $80.67, which was inline with its previous close. The fact that BLKB is trading near the top of its 52-week range is a positive indicator, as it suggests that the stock has been performing well over the past year. Additionally, the stock being above its 200-day simple moving average is another positive sign. Overall, BLKB stock showed positive performance on February 9, 2024, indicating that it is a stock worth considering for investors looking for potential growth opportunities.

BLKB Stock Performance on February 9, 2024: Revenue Holds Steady, Net Income Shows Improvement

BLKB Stock Performance on February 9, 2024: Revenue Holds Steady, Net Income Shows Improvement

On February 9, 2024, BLKB stock experienced mixed performance as the company’s total revenue held flat since the last quarter, while net income showed signs of improvement.

According to data sourced from CNN Money, BLKB reported a total revenue of $1.06 billion for the past year, representing a 14.05% increase compared to the previous year. However, the company’s total revenue remained unchanged at $277.63 million since the last quarter.

The stability in total revenue since the last quarter indicates that BLKB has been able to maintain its revenue streams despite potential challenges or fluctuations in the market.

In terms of net income, BLKB reported a loss of -$45.41 million for the past year, reflecting a significant decrease of 896.89% compared to the previous year. However, the company’s net income improved to $9.02 million in the last quarter, representing a notable increase of 328.36% since the previous quarter.

The improvement in net income since the last quarter is a positive development for BLKB. It indicates that the company has been able to reduce its losses and generate more profit in recent months.

Examining the earnings per share (EPS) figures, BLKB reported an EPS of -$0.88 for the past year, reflecting a significant decrease of 845.55% compared to the previous year. However, the company’s EPS increased to $0.17 in the last quarter, representing a substantial improvement of 325.26% since the previous quarter.

The improvement in EPS since the last quarter indicates that BLKB has been able to generate more earnings per outstanding share, which is a positive signal for investors.

Overall, BLKB’s stock performance on February 9, 2024, showcased a stable total revenue since the last quarter, indicating the company’s ability to maintain its revenue streams. Furthermore, the company’s net income showed signs of improvement, with a significant increase since the last quarter. This improvement in net income was also reflected in the earnings per share figures, which demonstrated substantial growth since the previous quarter.

Investors and analysts will likely closely monitor BLKB’s financial performance in the coming quarters to assess the sustainability of its revenue and profitability growth. It will be interesting to see if BLKB can continue to build on its recent improvements and deliver consistent positive results in the future.

Tags: BLKB
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finances

Positive Analyst Outlook and Price Targets for Intercontinental Exchange ICE Stock

Beverages Industry Markets and money

PepsiCo Faces Revenue Decline Despite Surpassing Earnings Expectations

Finance_Commercial (2)

Embecta Corps Positive Financial Results Overshadowed by Disappointing Guidance

Recommended

Marvell Technology Stock

Marvell Technology Emerges as Key Player in AI Infrastructure Boom

1 month ago
Novo Nordisk Stock

Danish Pharma Giant Novo Nordisk Faces Diverging Analyst Views

1 month ago
Finance_Investment (5)

Anticipation Builds as FirstService Prepares to Release Quarterly Earnings Report

2 years ago
Viking Therapeutics Stock

Acquisition Speculation Fuels Viking Therapeutics Stock Surge

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

DuPont Faces Critical Test as Quarterly Results Loom

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

Trending

BioNTech Stock
Analysis

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

by Andreas Sommer
November 6, 2025
0

BioNTech presents investors with a complex financial picture marked by contradictory signals. The German biotech firm reported...

Illumina Stock

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

November 6, 2025
Iovance Stock

Iovance Faces Critical Test as Q3 Earnings Approach

November 6, 2025
DuPont de Nemours Stock

DuPont Faces Critical Test as Quarterly Results Loom

November 6, 2025
Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise
  • China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally
  • Iovance Faces Critical Test as Q3 Earnings Approach

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com